Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGUS Trial
2024-518628-57-00Phase 3Authorised
- Sponsor
- Epygenix Therapeutics
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing EPX-100 (clemizole hydrochloride) with Placebo (2 arms). Primary endpoint: Percent change in CMS-28 in the Maintenance Period relative to baseline. Planned start Aug 2023; status: authorised.
02
Drugs
clemizole
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2024-518628-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518628-57-00.